Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
Psyence BioMed (Nasdaq: PBM) made a USD 3,500,000 follow-on investment in PsyLabs on August 15, 2025, after an earlier USD 500,000 investment in April 2025. The investment secures PsyLabs as a primary supplier of GMP‑grade psilocybin and ibogaine for Psyence BioMed’s clinical programs and aims to ensure an ethical, sustainable supply chain for the company’s nature-derived psychedelic pipeline.
The partnership highlights Psyence BioMed’s strategic focus on integrated supply from Southern Africa and notes certain executives provide consulting services to PsyLabs and collectively own less than 5% of PsyLabs.
Psyence BioMed (Nasdaq: PBM) ha effettuato un follow-on di USD 3.500.000 in PsyLabs il 15 agosto 2025, dopo un precedente investimento di USD 500.000 in aprile 2025. L'investimento assicura a PsyLabs il ruolo di fornitore principale di psilocibina GMP‑grade e ibogaina per i programmi clinici di Psyence BioMed e mira a garantire una catena di approvvigionamento etica e sostenibile per il portafoglio di psichedelici di derivazione naturale dell'azienda.
La partnership sottolinea l'orientamento strategico di Psyence BioMed verso una fornitura integrata dall'Africa meridionale e nota che alcuni dirigenti forniscono servizi di consulenza a PsyLabs e detengono collettivamente meno del 5% di PsyLabs.
Psyence BioMed (Nasdaq: PBM) realizó una inversión de seguimiento de USD 3.500.000 en PsyLabs el 15 de agosto de 2025, después de una inversión previa de USD 500.000 en abril de 2025. La inversión asegura a PsyLabs como proveedor principal de psilocibina de grado GMP e ibogaína para los programas clínicos de Psyence BioMed y tiene como objetivo garantizar una cadena de suministro ética y sostenible para la cartera de psicodélicos de origen natural de la empresa.
La asociación destaca el enfoque estratégico de Psyence BioMed hacia un suministro integrado desde el sur de África e indica que ciertos ejecutivos brindan servicios de consultoría a PsyLabs y poseen colectivamente menos del 5% de PsyLabs.
Psyence BioMed (나스닥: PBM)가 2025년 8월 15일에 PsyLabs에 USD 3,500,000의 후속 투자를 했으며, 2025년 4월의 이전 USD 500,000 투자에 이어졌다. 이 투자는 PsyLabs를 GMP 등급의 psilocybin과 ibogaine의 주요 공급자로 확보하여 Psyence BioMed의 임상 프로그램에 공급하고, 회사의 천연 추출 사이클을 위한 윤리적이고 지속 가능한 공급망을 확보하는 것을 목표로 한다.
파트너십은 Southern Africa로부터의 통합 공급에 대한 Psyence BioMed의 전략적 집중을 강조하고, 일부 경영진이 PsyLabs에 자문 서비스를 제공하며 총 5% 미만의 지분을 보유하고 있음을 주목한다.
Psyence BioMed (NASDAQ: PBM) a réalisé un investissement de suivie de USD 3 500 000 dans PsyLabs le 15 août 2025, après un investissement antérieur de USD 500 000 en avril 2025. L'investissement assure à PsyLabs le rôle de principal fournisseur de psilocybine de grade GMP et d'ibogaïne pour les programmes cliniques de Psyence BioMed et vise à garantir une chaîne d'approvisionnement éthique et durable pour le portefeuille de psychédéliques d'origine naturelle de l'entreprise.
Le partenariat met en évidence l'orientation stratégique de Psyence BioMed vers une fourniture intégrée depuis l'Afrique australe et note que certains cadres fournissent des services de conseil à PsyLabs et détiennent collectivement moins de 5% de PsyLabs.
Psyence BioMed (Nasdaq: PBM) tätigte eine Folgeinvestition in Höhe von USD 3.500.000 in PsyLabs am 15. August 2025, nach einer früheren Investition von USD 500.000 im April 2025. Die Investition sichert PsyLabs als primären Lieferanten von GMP‑grade Psilocybin und Ibogaine für die klinischen Programme von Psyence BioMed und zielt darauf ab, eine ethische, nachhaltige Lieferkette für das naturbasierte Psychedelics-Portfolio des Unternehmens zu gewährleisten.
Die Partnerschaft unterstreicht den strategischen Fokus von Psyence BioMed auf integrierte Versorgung aus dem Südlichen Afrika und stellt fest, dass bestimmte Führungskräfte PsyLabs Beratungsleistungen erbringen und gemeinsam unter 5% von PsyLabs besitzen.
Psyence BioMed (ناسداك: PBM) قامت باستثمار متابعة بقيمة 3,500,000 دولار أمريكي في PsyLabs في 15 أغسطس 2025، بعد استثمار سابق بقيمة 500,000 دولار أمريكي في أبريل 2025. يضمن الاستثمار لـ PsyLabs أن تكون مورداً رئيسياً لـpsilocybin ذو الدرجة GMP و ibogaine لبرامج Psyence BioMed السريرية ويهدف إلى ضمان سلسلة توريد أخلاقية ومستدامة لمجموعة المواد المخدرة المستمدة من الطبيعة لدى الشركة.
تسليط الضوء على الشراكة تركيز Psyence BioMed الاستراتيجي على الإمداد المتكامل من جنوب إفريقيا ويشير إلى أن بعض التنفيذيين يقدمون خدمات استشارية لـ PsyLabs ويملكون مجتمعين أقل من 5% من PsyLabs.
- Follow-on investment of USD 3,500,000 on August 15, 2025
- Prior USD 500,000 investment in April 2025
- Secures GMP‑grade supply of psilocybin and ibogaine
- First public company investment in Southern African production
- Concentration risk: reliance on a single primary supplier for APIs
- Related‑party ties: executives provide paid consulting to PsyLabs
- Related‑party ownership: certain insiders own less than 5% of PsyLabs
Insights
Psyence BioMed deepens supply-chain control with a
Psyence BioMed increased its stake in PsyLabs via a
The business mechanism is straightforward: capital infusion for a supplier improves supply visibility and reduces procurement risk for clinical work while strengthening the bilateral commercial relationship. The announcement also discloses related-party arrangements: certain executives and an independent director provide consulting services to PsyLabs for fees and collectively own less than
Key dependencies and risks noted in the disclosure include the actual delivery of GMP materials and the transparency of related-party arrangements. Monitor confirmations of API delivery schedules, any formal supplier agreements or quality certifications, and subsequent company disclosures about clinical program progress. Relevant near-term checkpoints include any future regulatory or clinical filings that reference PsyLabs supply and any updates to the scope of consulting relationships.
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs, today announced it has made a USD
This investment solidifies PsyLabs’ position as a primary supplier of high-quality, GMP-grade psychedelic compounds, including psilocybin and ibogaine, for Psyence BioMed’s clinical research programs. The enhanced collaboration ensures Psyence BioMed continues to have access to an ethical, sustainable, and reliable supply of premium psychedelic compounds to advance its clinical pipeline. This investment made on August 15th, 2025, follows-on from the previously made USD
“We are committed to advancing nature-derived psychedelics and building a responsible, global supply chain,” said Psyence BioMed Chief Executive Officer, Jody Aufrichtig. “This new investment is a deliberate step toward building a fully integrated company – from cultivation to clinical development. This strategic approach not only secures access to the highest quality compounds for our trials but also creates long-term value for our investors by ensuring sustainability, scalability, and competitive differentiation in a rapidly evolving market,” added Aufrichtig.
PsyLabs’ state-of-the-art facility in Southern Africa utilizes the region’s rich botanical heritage to produce psychedelic compounds under strict ethical and sustainable practices. Psyence BioMed is the first publicly listed company with a dedicated investment in Southern African psychedelic production, underscoring the Company’s commitment to accessing regional expertise while advancing global psychedelic research.
“This continued investment from Psyence BioMed is a testament to the strength of our partnership and the quality of our products,” said Tony Budden, CEO of PsyLabs. “We are proud to support Psyence BioMed’s pioneering clinical work with our premium, sustainably produced compounds.”
With this expanded partnership, Psyence BioMed strengthens its leadership position in the emerging psychedelic therapeutics sector, advancing both near-term clinical development and long-term commercial opportunities.
Certain executives, including the Chief Executive Officer, the Chief Financial Officer and the General Counsel, and an independent director, of Psyence BioMed, provide consulting services to PsyLabs in exchange for consulting fees. Such individuals own less than
About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The name ‘Psyence’ merges ‘psychedelics’ and ‘science,’ reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Learn more at www.psyencebiomed.com and on LinkedIn.
About PsyLabs
PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.
PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708
Investor Contact:
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.
Forward-looking statements in this communication include statements regarding the advancement of the Company's clinical pipeline and the creation of long-term shareholder value. These forward-looking statements are based on a number of assumptions, including the assumption that all parties involved in the ibogaine supply chain will retain such valid permits and licenses as may be required to carry out their activities and that the demand for psychedelic-containing products and related therapy will continue to increase. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, among others: (i) delays in the execution of the Company's drug development and clinical trial pipeline; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.
These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
FAQ
How much did Psyence BioMed (PBM) invest in PsyLabs on August 15, 2025?
What prior investment did PBM make in PsyLabs before August 2025?
How does the PsyLabs investment affect PBM’s supply of psilocybin and ibogaine?
Does Psyence BioMed disclose any related‑party relationships with PsyLabs?
Where are PsyLabs’ production facilities located referenced by PBM?
